Keywords: AstraZeneca, MedImmune, MEDI-573, Preclincial results, Cancer progression
AstraZeneca unit highlights potential for MEDI-573 as inhibitor of development and progression of cancer
Article | 21 January 2011
Anglo-Swedish drug major AstraZeneca (LSE: AZN) says its US subsidiary MedImmune's Oncology group has announced preclinical results showing that MEDI-573, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
